Angle initiates launch of cancer diagnostic product for market research

Angle, an AIM-listed specialist medtech company, has initiated the launch of its Parsortix non-invasive cancer diagnostic product for the research market.

Angle, an AIM-listed specialist medtech company, has initiated the launch of its Parsortix non-invasive cancer diagnostic product for the research market.

The product is based on taking a blood test, and the system either counts circulating tumour cells (CTCs) in the blood or captures and recovers the CTCs as a "liquid biopsy" for molecular analysis of the cells.

To accelerate deployment of the Parsortix system, Angle is in the process of placing machines on loan with a limited number of key users worldwide. The key users' research work will contribute to the data sets that Parsortix is developing to support regulatory submissions for marketing and Food and Drug Administration approval.

Andrew Newland, the founder and Chief Executive of the group, said: "Launch of the Parsortix system in the research market is a key milestone moving the business from the development stage into commercialisation. We are now intending to move rapidly to establish some key collaborations with leading cancer research groups."

The share price rose 15.79% to 66p by 13:50.

NR

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Oil producers are back at their Covid-19 lows – is it time to buy?
Oil

Oil producers are back at their Covid-19 lows – is it time to buy?

With demand for oil hammered by Covid-19 and talk of “peak oil demand”, there are lots of good reasons to be bearish on oil producers. So, asks John S…
22 Sep 2020
The rising dollar is proving bad news for most other assets – will it last?
Investment strategy

The rising dollar is proving bad news for most other assets – will it last?

Precious metals, stocks and pretty much every other asset has taken a tumble as the US dollar strengthens. Dominic Frisby looks at how long this trend…
23 Sep 2020
Why you should stuff your end-of-pandemic portfolio with Chinese stocks
China stockmarkets

Why you should stuff your end-of-pandemic portfolio with Chinese stocks

For an end-of-pandemic portfolio, you need assets that can cope with today’s volatility. And that, says Merryn Somerset Webb, means Chinese stocks.
14 Sep 2020